Multimedia

Multimedia

Podcasts and video interviews with researchers, commentators, and experts in the field

video

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

Sunday, January 1st, 2017
Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit...
video

Ruxolitinib in CMML: Study Shows Promising Results

Monday, October 31st, 2016
Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with...
video

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

Tuesday, August 2nd, 2016
Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with...
video

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

Tuesday, August 2nd, 2016
María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still...
video

What Was Hot at ASH 2015?

Monday, August 1st, 2016
ASH Clinical News’ Editor-in-Chief Mikkael A. Sekeres, MD, MS, shares his highlights of the 2015 ASH Annual Meeting.
video

Multiple Advances in Multiple Myeloma

Monday, August 1st, 2016
Sagar Lonial, MD, reviews the recent advances in the treatment of multiple myeloma, including how to sequence the newly approved myeloma drugs and their...
video

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

Friday, July 22nd, 2016
Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid...
video

Options for Treating the High-Risk APL Patient

Sunday, June 5th, 2016
Alan Burnett, MD, takes a look at the combination of ATRA + ATO + GO in high-risk acute promyelocytic leukemia (APL) patients, the complications...
video

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

Thursday, April 21st, 2016
Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more...
Advertisement

Current Issue

April 2017, Volume 3, Issue 5

This issue examines the art and science of myeloma drug sequencing, Mikkael Sekeres' letter to the ABIM, highlights from the 16th International Myeloma Workshop, and more.